Skip to main content
Erschienen in: Current Infectious Disease Reports 2/2017

01.02.2017 | Neurological Infections (J Lyons, Section Editor)

The Viral Connection to Glioblastoma

verfasst von: J. Ricardo McFaline-Figueroa, Patrick Y. Wen

Erschienen in: Current Infectious Disease Reports | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The high incidence of and mortality from glioblastoma are matched by a lack of effective therapies. Previous research suggests an association between viral infection and glioma formation. In this manuscript, we review the available evidence for this association and the efficacy of treatment strategies targeted against viral infection.

Recent Findings

We find that while a wide array of viruses can drive glioma tumor formation in vitro and in xenograft models, the most convincing association is with the human Cytomegalovirus (HCMV). Detection of HCMV in glioblastoma resected from living patients suggests it may either drive gliomagenesis, support tumor growth, or reactivate silently in these tumors. However, there is conflicting evidence on its ubiquity and its role in tumor formation. Valganciclovir may extend survival in glioblastoma patients, though adequate data on its efficacy and mechanism of action are lacking. Immunotherapy provides the opportunity to specifically target the virus and possibly, glioblastoma, though there are no large, randomized trials testing its efficacy to date.

Summary

Overall, despite mounting evidence for an association between HCMV and glioblastoma, its role as an oncogenic factor and a therapeutic target remains controversial.
Literatur
1.
Zurück zum Zitat Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-Oncology. 2015;17 Suppl 4:iv1–62.CrossRefPubMedPubMedCentral Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-Oncology. 2015;17 Suppl 4:iv1–62.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro-Oncology. 2014;16:896–913.CrossRefPubMedPubMedCentral Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro-Oncology. 2014;16:896–913.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Shein HM. Neoplastic transformation of hamster astrocytes in vitro by simian virus 40 and polyoma virus. Science. 1968;159:1476–7.CrossRefPubMed Shein HM. Neoplastic transformation of hamster astrocytes in vitro by simian virus 40 and polyoma virus. Science. 1968;159:1476–7.CrossRefPubMed
4.
Zurück zum Zitat Rabotti GF, Anderson WR, Sellers RL. Oncogenic activity of Mill Hill (Harris) strain of Rous sarcoma virus for hamsters. Nature. 1965;206:946–7.CrossRefPubMed Rabotti GF, Anderson WR, Sellers RL. Oncogenic activity of Mill Hill (Harris) strain of Rous sarcoma virus for hamsters. Nature. 1965;206:946–7.CrossRefPubMed
5.
Zurück zum Zitat Rapp F, Pauluzzi S, Waltz TA, Burdine JA, Matsen FA, Levy B. Induction of brain tumors in newborn hamsters by simian adenovirus SA7. Cancer Res. 1969;29:1173–8.PubMed Rapp F, Pauluzzi S, Waltz TA, Burdine JA, Matsen FA, Levy B. Induction of brain tumors in newborn hamsters by simian adenovirus SA7. Cancer Res. 1969;29:1173–8.PubMed
6.
Zurück zum Zitat Yung WK, Blank NK, Vick NA. “Glioblastoma”. Induction of a reproducible autochonous tumor in rats with murine sarcoma virus. Neurology. 1976;26:76–83.CrossRefPubMed Yung WK, Blank NK, Vick NA. “Glioblastoma”. Induction of a reproducible autochonous tumor in rats with murine sarcoma virus. Neurology. 1976;26:76–83.CrossRefPubMed
7.••
Zurück zum Zitat Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62:3347–50. This study first detected human cytomegalovirus DNA, RNA and proteins in human glioblastoma post-surgical samples.PubMed Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62:3347–50. This study first detected human cytomegalovirus DNA, RNA and proteins in human glioblastoma post-surgical samples.PubMed
8.
Zurück zum Zitat Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-Oncology. 2008;10:10–8.CrossRefPubMedPubMedCentral Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-Oncology. 2008;10:10–8.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Lucas KG, Bao L, Bruggeman R, Dunham K, Specht C. The detection of CMV pp 65 and IE1 in glioblastoma multiforme. J Neurooncol. 2011;103:231–8.CrossRefPubMed Lucas KG, Bao L, Bruggeman R, Dunham K, Specht C. The detection of CMV pp 65 and IE1 in glioblastoma multiforme. J Neurooncol. 2011;103:231–8.CrossRefPubMed
10.
Zurück zum Zitat Lau SK, Chen Y-Y, Chen W-G, Diamond DJ, Mamelak AN, Zaia JA, et al. Lack of association of cytomegalovirus with human brain tumors. Mod Pathol. 2005;18:838–43.CrossRefPubMed Lau SK, Chen Y-Y, Chen W-G, Diamond DJ, Mamelak AN, Zaia JA, et al. Lack of association of cytomegalovirus with human brain tumors. Mod Pathol. 2005;18:838–43.CrossRefPubMed
11.
Zurück zum Zitat Poltermann S, Schlehofer B, Steindorf K, Schnitzler P, Geletneky K, Schlehofer JR. Lack of association of herpesviruses with brain tumors. J Neurovirol. 2006;12:90–9.CrossRefPubMed Poltermann S, Schlehofer B, Steindorf K, Schnitzler P, Geletneky K, Schlehofer JR. Lack of association of herpesviruses with brain tumors. J Neurovirol. 2006;12:90–9.CrossRefPubMed
12.
Zurück zum Zitat Priel E, Wohl A, Teperberg M, Nass D, Cohen ZR. Human cytomegalovirus viral load in tumor and peripheral blood samples of patients with malignant gliomas. J Clin Neurosci. 2015;22:326–30.CrossRefPubMed Priel E, Wohl A, Teperberg M, Nass D, Cohen ZR. Human cytomegalovirus viral load in tumor and peripheral blood samples of patients with malignant gliomas. J Clin Neurosci. 2015;22:326–30.CrossRefPubMed
13.
Zurück zum Zitat Lin C-TM, Leibovitch EC, Almira-Suarez MI, Jacobson S. Human herpesvirus multiplex ddPCR detection in brain tissue from low- and high-grade astrocytoma cases and controls. Infect Agent Cancer. 2016;11:32. BioMed Central.CrossRefPubMedPubMedCentral Lin C-TM, Leibovitch EC, Almira-Suarez MI, Jacobson S. Human herpesvirus multiplex ddPCR detection in brain tissue from low- and high-grade astrocytoma cases and controls. Infect Agent Cancer. 2016;11:32. BioMed Central.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Scheurer ME, El-Zein R, Bondy ML, Harkins L, Cobbs CS. RE: “Lack of association of herpesviruses with brain tumors”. J Neurovirol. 2007;13:85. author reply 86–7.CrossRefPubMed Scheurer ME, El-Zein R, Bondy ML, Harkins L, Cobbs CS. RE: “Lack of association of herpesviruses with brain tumors”. J Neurovirol. 2007;13:85. author reply 86–7.CrossRefPubMed
15.
Zurück zum Zitat Poland SD, Costello P, Dekaban GA, Rice GP. Cytomegalovirus in the brain: in vitro infection of human brain-derived cells. J Infect Dis. 1990;162:1252–62.CrossRefPubMed Poland SD, Costello P, Dekaban GA, Rice GP. Cytomegalovirus in the brain: in vitro infection of human brain-derived cells. J Infect Dis. 1990;162:1252–62.CrossRefPubMed
16.
Zurück zum Zitat Ogura T, Tanaka J, Kamiya S, Sato H, Ogura H, Hatano M. Human cytomegalovirus persistent infection in a human central nervous system cell line: production of a variant virus with different growth characteristics. J Gen Virol. 1986;67(Pt 12):2605–16.CrossRefPubMed Ogura T, Tanaka J, Kamiya S, Sato H, Ogura H, Hatano M. Human cytomegalovirus persistent infection in a human central nervous system cell line: production of a variant virus with different growth characteristics. J Gen Virol. 1986;67(Pt 12):2605–16.CrossRefPubMed
17.
Zurück zum Zitat Michaelis M, Doerr HW, Cinatl J. The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia. 2009;11:1–9.CrossRefPubMedPubMedCentral Michaelis M, Doerr HW, Cinatl J. The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia. 2009;11:1–9.CrossRefPubMedPubMedCentral
18.•
Zurück zum Zitat Stragliotto G, Rahbar A, Solberg NW, Lilja A, Taher C, Orrego A, et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer. 2013;133:1204–13. This small, exploratory, double-blind, randomized control trial showed no benefit to adjuvant valganciclovir in regards to tumor progression, overall survival or progression free survival at 6 months.CrossRefPubMed Stragliotto G, Rahbar A, Solberg NW, Lilja A, Taher C, Orrego A, et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer. 2013;133:1204–13. This small, exploratory, double-blind, randomized control trial showed no benefit to adjuvant valganciclovir in regards to tumor progression, overall survival or progression free survival at 6 months.CrossRefPubMed
19.•
Zurück zum Zitat Söderberg-Nauclér C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med. 2013;369:985–6. This retrospective analysis of the VIGAS trial, as well as other, non-study patients receiving valganciclovir, suggests a survival benefit to receiving at least 6 months of adjuvant valganciclovir.CrossRefPubMed Söderberg-Nauclér C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med. 2013;369:985–6. This retrospective analysis of the VIGAS trial, as well as other, non-study patients receiving valganciclovir, suggests a survival benefit to receiving at least 6 months of adjuvant valganciclovir.CrossRefPubMed
20.
Zurück zum Zitat Weller M, Soffietti R, Brada M. The legend of cytomegalovirus and glioblastoma lives on. Neuro-Oncology. 2014;16:166.CrossRefPubMed Weller M, Soffietti R, Brada M. The legend of cytomegalovirus and glioblastoma lives on. Neuro-Oncology. 2014;16:166.CrossRefPubMed
21.
Zurück zum Zitat Liu C-J, Hu Y-W. Immortal time bias in retrospective analysis: is there a survival benefit in patients with glioblastoma who received prolonged treatment of adjuvant valganciclovir? Int J Cancer. 2014;135:250–1.CrossRefPubMed Liu C-J, Hu Y-W. Immortal time bias in retrospective analysis: is there a survival benefit in patients with glioblastoma who received prolonged treatment of adjuvant valganciclovir? Int J Cancer. 2014;135:250–1.CrossRefPubMed
22.
Zurück zum Zitat Söderberg-Nauclér C, Peredo I, Rahbar A, Hansson F, Nordlund A, Stragliotto G. Use of Cox regression with treatment status as a time-dependent covariate to re-analyze survival benefit excludes immortal time bias effect in patients with glioblastoma who received prolonged adjuvant treatment with valganciclovir. Int J Cancer. 2014;135:248–9.CrossRefPubMed Söderberg-Nauclér C, Peredo I, Rahbar A, Hansson F, Nordlund A, Stragliotto G. Use of Cox regression with treatment status as a time-dependent covariate to re-analyze survival benefit excludes immortal time bias effect in patients with glioblastoma who received prolonged adjuvant treatment with valganciclovir. Int J Cancer. 2014;135:248–9.CrossRefPubMed
23.
Zurück zum Zitat Peng C, Wang J, Tanksley JP, Mobley BC, Ayers GD, Moots PL, et al. Valganciclovir and bevacizumab for recurrent glioblastoma: a single-institution experience. Mol Clin Oncol. 2016;4:154–8.PubMed Peng C, Wang J, Tanksley JP, Mobley BC, Ayers GD, Moots PL, et al. Valganciclovir and bevacizumab for recurrent glioblastoma: a single-institution experience. Mol Clin Oncol. 2016;4:154–8.PubMed
24.
Zurück zum Zitat Baryawno N, Rahbar A, Wolmer-Solberg N, Taher C, Odeberg J, Darabi A, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest. 2011;121:4043–55.CrossRefPubMedPubMedCentral Baryawno N, Rahbar A, Wolmer-Solberg N, Taher C, Odeberg J, Darabi A, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest. 2011;121:4043–55.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Hellstrand K, Martner A, Bergström T. Valganciclovir in patients with glioblastoma. N Engl J Med. 2013;369:2066.CrossRefPubMed Hellstrand K, Martner A, Bergström T. Valganciclovir in patients with glioblastoma. N Engl J Med. 2013;369:2066.CrossRefPubMed
26.
Zurück zum Zitat Söderberg-Nauclér C, Peredo I, Stragliotto G. Valganciclovir in patients with glioblastoma. N Engl J Med. 2013;369:2066–7.CrossRefPubMed Söderberg-Nauclér C, Peredo I, Stragliotto G. Valganciclovir in patients with glioblastoma. N Engl J Med. 2013;369:2066–7.CrossRefPubMed
27.
Zurück zum Zitat Wrensch M, Weinberg A, Wiencke J, Miike R, Barger G, Kelsey K. Prevalence of antibodies to four herpesviruses among adults with glioma and controls. Am J Epidemiol. 2001;154:161–5.CrossRefPubMed Wrensch M, Weinberg A, Wiencke J, Miike R, Barger G, Kelsey K. Prevalence of antibodies to four herpesviruses among adults with glioma and controls. Am J Epidemiol. 2001;154:161–5.CrossRefPubMed
28.
Zurück zum Zitat Rahbar A, Peredo I, Solberg NW, Taher C, Dzabic M, Xu X, et al. Discordant humoral and cellular immune responses to Cytomegalovirus (CMV) in glioblastoma patients whose tumors are positive for CMV. OncoImmunology. 2015;4:e982391.CrossRefPubMedPubMedCentral Rahbar A, Peredo I, Solberg NW, Taher C, Dzabic M, Xu X, et al. Discordant humoral and cellular immune responses to Cytomegalovirus (CMV) in glioblastoma patients whose tumors are positive for CMV. OncoImmunology. 2015;4:e982391.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Hadaczek P, Ozawa T, Soroceanu L, Yoshida Y, Matlaf L, Singer E, et al. Cidofovir: a novel antitumor agent for glioblastoma. Clin Cancer Res. 2013;19:6473–83.CrossRefPubMedPubMedCentral Hadaczek P, Ozawa T, Soroceanu L, Yoshida Y, Matlaf L, Singer E, et al. Cidofovir: a novel antitumor agent for glioblastoma. Clin Cancer Res. 2013;19:6473–83.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Kast RE, Ramiro S, Lladó S, Toro S, Coveñas R, Muñoz M. Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells. J Neurooncol. 2016;126:425–31. Springer US.CrossRefPubMed Kast RE, Ramiro S, Lladó S, Toro S, Coveñas R, Muñoz M. Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells. J Neurooncol. 2016;126:425–31. Springer US.CrossRefPubMed
31.
Zurück zum Zitat Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med. 2008;359:539–41.CrossRefPubMedPubMedCentral Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med. 2008;359:539–41.CrossRefPubMedPubMedCentral
32.•
Zurück zum Zitat Mitchell DA, Batich KA, Gunn MD, Huang M-N, Sanchez-Perez L, Nair SK, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015;519:366–9. This small, double-blinded, randomized-control trial of vaccination with pp65-exposed dendritic cells (a HCMV antigen) after tetanus/diphteria toxin preconditioning showed increased progression-free survival and overall survival in glioblastoma patients.CrossRefPubMedPubMedCentral Mitchell DA, Batich KA, Gunn MD, Huang M-N, Sanchez-Perez L, Nair SK, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015;519:366–9. This small, double-blinded, randomized-control trial of vaccination with pp65-exposed dendritic cells (a HCMV antigen) after tetanus/diphteria toxin preconditioning showed increased progression-free survival and overall survival in glioblastoma patients.CrossRefPubMedPubMedCentral
33.
34.
Zurück zum Zitat Crough T, Beagley L, Smith C, Jones L, Walker DG, Khanna R. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol Cell Biol. 2012;90:872–80.CrossRefPubMed Crough T, Beagley L, Smith C, Jones L, Walker DG, Khanna R. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol Cell Biol. 2012;90:872–80.CrossRefPubMed
35.
Zurück zum Zitat Schuessler A, Smith C, Beagley L, Boyle GM, Rehan S, Matthews K, et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 2014;74:3466–76.CrossRefPubMed Schuessler A, Smith C, Beagley L, Boyle GM, Rehan S, Matthews K, et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 2014;74:3466–76.CrossRefPubMed
Metadaten
Titel
The Viral Connection to Glioblastoma
verfasst von
J. Ricardo McFaline-Figueroa
Patrick Y. Wen
Publikationsdatum
01.02.2017
Verlag
Springer US
Erschienen in
Current Infectious Disease Reports / Ausgabe 2/2017
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-017-0563-z

Weitere Artikel der Ausgabe 2/2017

Current Infectious Disease Reports 2/2017 Zur Ausgabe

Cardiovascular Infections (B Hoen, Section Editor)

Cardiac Imaging of Infective Endocarditis, Echo and Beyond

Cardiovascular Infections (B Hoen, Section Editor)

Antibiotic Prophylaxis of Infective Endocarditis

Neurological Infections (J Lyons, Section Editor)

Neurologic Manifestation of Chikungunya Virus

Neurological Infections (J Lyons, Section Editor)

Infectious Complications of Novel Multiple Sclerosis Therapies

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.